Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Ivosidenib is the first approved drug of the IDH1 inhibitor class. It works by inhibiting isocitrate dehydrogenase-1 (IDH1) to reduce the abnormal production of 2-hydroxyglutarate ···【more】
Article source：Captain MedicineRelease date：2025-12-31Recommended：88
Ivosidenib targets a specific gene mutation called IDH1, which may affect your bone marrow.What are the indications for Ivosidenib?The IDH1 mutation impairs the development of imma···【more】
Article source：Captain MedicineRelease date：2025-12-31Recommended：63
Ivosidenib can be used for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients who have received prior therapy. For such patients, conventional chemoth···【more】
Article source：Captain MedicineRelease date：2025-12-31Recommended：69
Ivosidenib, either as a monotherapy or in combination with azacitidine, is indicated for the treatment of newly diagnosed acute myeloid leukemia (AML) in patients aged ≥ 75 years o···【more】
Article source：Captain MedicineRelease date：2025-12-31Recommended：90
Tibsovo® (ivosidenib tablets) is the first tumor metabolism-targeted therapy approved for use in combination with azacitidine for the treatment of adult patients with newly diagnos···【more】
Article source：Captain MedicineRelease date：2025-12-31Recommended：75
On October 24, 2023, Servier, a leader in the oncology field dedicated to bringing tomorrow’s hope to patients, announced today that the U.S. Food and Drug Administration (FDA) has···【more】
Article source：Captain MedicineRelease date：2025-12-31Recommended：91
LuciusVersionofIbrutinib:DosageandAdministration,Indications,PrecautionsIndicationsAdult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.Adult···【more】
Article source：Captain MedicineRelease date：2025-12-18Recommended：76
LuciusVersionofDeucravacitinib:DosageandAdministration,Indications,PrecautionsIndicationsDeucravacitinib is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adul···【more】
Article source：Captain MedicineRelease date：2025-12-18Recommended：78
LuciusVersionofDaprodustat:DosageandAdministration,Indications,PrecautionsDaprodustat is indicated for the treatment of anemia caused by chronic kidney disease in adult patients wh···【more】
Article source：Captain MedicineRelease date：2025-12-17Recommended：80
LuciusVersionofDacomitinib:DosageandAdministration,Indications,PrecautionsIndicationsDacomitinib is indicated for the first-line treatment of patients with metastatic non-small cel···【more】
Article source：Captain MedicineRelease date：2025-12-17Recommended：138
Lucius Version of Momelotinib: Dosage and Administration, Indications, PrecautionsIndicationsMomelotinib is indicated for the treatment of adult patients with anemia associated wit···【more】
Article source：Captain MedicineRelease date：2025-12-16Recommended：84
LuciusVersionofPirtobrutinib:DosageandAdministration,Indications,PrecautionsIndicationsPirtobrutinib is indicated for the treatment of adult patients with relapsed or refractory ma···【more】
Article source：Captain MedicineRelease date：2025-12-16Recommended：96
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：1692025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：4082024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：1632025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：1832025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：1632025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：1992025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：1772025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：1722025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
